NKX101
Relapsed/Refractory Acute Myeloid Leukemia (AML) / Higher-Risk Myelodysplastic Syndromes (MDS)
Key Facts
About Nkarta
Nkarta is advancing a new class of cell therapies using engineered natural killer (NK) cells to target and destroy cancer. The company's core technology focuses on developing allogeneic, or 'off-the-shelf,' cell therapies from healthy donor cells, which are engineered with chimeric antigen receptors (CARs) and membrane-bound cytokines to enhance their anti-tumor activity. Key milestones include advancing its lead candidates, NKX101 and NKX019, into clinical trials for hematologic cancers and solid tumors, supported by strategic partnerships and public market funding. Nkarta aims to overcome the limitations of autologous CAR-T therapies by creating readily available, potent, and scalable NK cell products.
View full company profileAbout Nkarta
Nkarta is advancing a new class of cell therapies using engineered natural killer (NK) cells to target and destroy cancer. The company's core technology focuses on developing allogeneic, or 'off-the-shelf,' cell therapies from healthy donor cells, which are engineered with chimeric antigen receptors (CARs) and membrane-bound cytokines to enhance their anti-tumor activity. Key milestones include advancing its lead candidates, NKX101 and NKX019, into clinical trials for hematologic cancers and solid tumors, supported by strategic partnerships and public market funding. Nkarta aims to overcome the limitations of autologous CAR-T therapies by creating readily available, potent, and scalable NK cell products.
View full company profile